Trial NCT04412538
Publication Che Y, Clin Infect Dis, 2020
Primary outcome on the report: Seroconversion rates of the anti-SARS-CoV-2 neutralizing antibody and ELISA IgG antibody at days 14 (0, 14 procedure) and 28 (0, 28 procedure), respectively, after the boost immunization

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.